Publication | Closed Access

Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer

Breast OncologyMedicineImmunologyPathologyImmune Checkpoint InhibitorBreast CancerSubgroup AnalysisTrastuzumab Versus TrastuzumabCancer TreatmentOncologyRadiation Oncology